Details of Disease

Disease Name

Disease Class

EA80-EA89: Eczema

Disease Hierarchy

DIS01GPL: Grass pollen hypersensitivity

DIS3N7H0: Eczema

ICD-11

ICD-11: EA80-EA89

Expand ICD-11

'EA8Z

Expand ICD-10

'L20-L30; 'L20.9; 'L27; 'L27.2; 'L27.8; 'L27.9; 'L30; 'L30.9

Disease Identifiers

MONDO ID

MONDO_0001836

MESH ID

D000568

UMLS CUI

C0002453

MedGen ID

8016

HPO ID

HP:0000141

SNOMED CT ID

14302001

General Information of Disease (ID: DIS3N7H0)

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Juniper tar	DM0WYFG	Approved	NA	[1]
Prednisone	DM2HG4X	Approved	Small molecular drug	[2]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 6 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AOB102	DMLCO00	Phase 2	NA	[2]
ASN002	DM92X7N	Phase 2	NA	[2]
LAS-41002	DM3WY0B	Phase 2	NA	[3]
LAS-41003	DMYFC22	Phase 2	NA	[4]
LEO 124249	DM7W0JE	Phase 2	NA	[2]
CJ-12255	DMRQX9H	Phase 1	NA	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

This Disease is Treated as An Indication in 1 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
SR-2566	DM238DR	Terminated	NA	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	ClinicalTrials.gov (NCT01119313) Study to Investigate Skin Conditions and Patient Assessment of LAS 41002 in the Treatment of Atopic Eczema. U.S. National Institutes of Health.
4	ClinicalTrials.gov (NCT01020994) Efficacy and Safety of LAS41003 in the Treatment of Superficial Infected Eczema. U.S. National Institutes of Health.
5	HIV ANTIRETROVIRAL DRUG SUSCEPTIBILITY AND DRUG INTERACTIONS (DIRECTOR: MARK MANAK). The Children's Hospital of Philadelphia.
6	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007241)